HighTower Advisors LLC reduced its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,343 shares of the medical instruments supplier’s stock after selling 10,799 shares during the quarter. HighTower Advisors LLC’s holdings in Becton, Dickinson and Company were worth $31,312,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Stronghold Wealth Management L.L.C. bought a new stake in Becton, Dickinson and Company during the 4th quarter worth about $222,000. TD Private Client Wealth LLC increased its stake in shares of Becton, Dickinson and Company by 7.4% during the 4th quarter. TD Private Client Wealth LLC now owns 14,673 shares of the medical instruments supplier’s stock worth $2,848,000 after purchasing an additional 1,012 shares during the last quarter. Tucker Asset Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $34,000. Gabelli Funds LLC increased its stake in shares of Becton, Dickinson and Company by 4.4% during the 4th quarter. Gabelli Funds LLC now owns 44,295 shares of the medical instruments supplier’s stock worth $8,596,000 after purchasing an additional 1,850 shares during the last quarter. Finally, North Dakota State Investment Board acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $1,904,000. 86.97% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. Jefferies Financial Group lowered their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. JPMorgan Chase & Co. lowered their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. TD Cowen lowered their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Finally, Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $184.86.
Becton, Dickinson and Company Stock Up 1.0%
Shares of BDX opened at $147.76 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The firm has a market cap of $40.71 billion, a P/E ratio of 37.41, a price-to-earnings-growth ratio of 10.35 and a beta of 0.22. The firm’s 50-day simple moving average is $152.83 and its 200 day simple moving average is $178.07. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.
Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
